Menu Search
Equities

Novacyt SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
NYZ:MUN

Novacyt SA

Actions
  • Price (EUR)0.4105
  • Today's Change0.001 / 0.24%
  • Shares traded--
  • 1 Year change-30.78%
  • Beta0.1584
Data delayed at least 15 minutes, as of Mar 03 2026 08:12 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Novacyt SA is a France-based company providing biotechnological solutions. The Company develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. It provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The Company develops secure automated cytology named NovaPrep Processor System. It offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. It creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle.

  • Revenue in EUR (TTM)21.91m
  • Net income in EUR-31.84m
  • Incorporated2006
  • Employees234.00
  • Location
    Novacyt SA131 Boulevard Carnot, Le VesinetVELIZY VILLACOUBLAY 78110FranceFRA
  • Phone+33 139465104
  • Fax+33 130700532
  • Websitehttps://novacyt.com/fr
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.